Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. We show 21 historical shares outstanding datapoints in our coverage of LUMO's shares outstanding history.
Understanding the changing numbers of LUMO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LUMO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LUMO by allowing them to research LUMO shares outstanding history
as well as any other stock in our coverage universe. |
Free LUMO Email Alerts:
Video: Shares Outstanding Importance
